SURPASS-2 Trial: Tirzepatide Beats Semaglutide Head-to-Head in Type 2 Diabetes
Medically reviewed by Dr. James Whitfield, DO, FACOI
The SURPASS-2 trial, published in the New England Journal of Medicine in 2021 by Frías et al., was the first head-to-head comparison of tirzepatide versus semaglutide. In 1,879 patients with type 2 diabetes, all three tirzepatide doses produced significantly greater HbA1c reductions and weight loss than semaglutide 1mg — establishing tirzepatide's superiority over the leading GLP-1 agonist.
SURPASS-2: The Trial That Changed the Competitive Landscape
The SURPASS-2 trial is arguably the most consequential study in the tirzepatide clinical program. Published in the New England Journal of Medicine in August 2021 by Frías et al., this was the first randomized, head-to-head comparison of tirzepatide against semaglutide — the reigning champion of GLP-1 receptor agonists. The results unequivocally demonstrated tirzepatide's superiority across both glycemic and weight endpoints [1].
Study Design
SURPASS-2 was a 40-week, open-label, randomized Phase 3 trial conducted at 128 sites across 13 countries. The study enrolled 1,879 adults with type 2 diabetes inadequately controlled on metformin alone (≥1,500 mg/day for ≥3 months).
Randomization:
The choice of semaglutide 1 mg (Ozempic) as the comparator was significant — at the time of trial design, this was the highest approved dose of semaglutide for type 2 diabetes and was considered the gold standard for injectable GLP-1 receptor agonist therapy.
---
> Considering adding this to your protocol? Telegenix provides physician-supervised peptide and hormone optimization programs tailored to your bloodwork and goals. Schedule your consultation.
---
Head-to-Head Glycemic Results
Tirzepatide demonstrated superiority at all three doses:
Mean HbA1c Change from Baseline (~8.3%):
Treatment Difference vs. Semaglutide:
HbA1c Target Achievement (<7.0%):
HbA1c <5.7% (Normal Range):
Nearly half of patients on tirzepatide 15 mg achieved a completely normal HbA1c — more than double the rate with semaglutide [1].
Head-to-Head Weight Loss Results
The weight loss comparison was equally decisive:
Mean Body Weight Change:
Treatment Difference vs. Semaglutide:
At the highest dose, tirzepatide produced nearly double the weight loss of semaglutide 1 mg. Even the lowest tirzepatide dose (5 mg) produced statistically significantly more weight loss than semaglutide [1].
Why Does Tirzepatide Outperform Semaglutide?
The superiority of tirzepatide is attributed to its dual mechanism:
The GIP Component:
Pharmacological Considerations:
Safety Comparison
The safety profiles were broadly similar:
Gastrointestinal Events:
Hypoglycemia (<54 mg/dL):
Discontinuation due to adverse events:
Notably, despite producing significantly greater weight loss and glucose lowering, tirzepatide did not have meaningfully higher rates of adverse events compared to semaglutide [1].
The Dosing Caveat
An important consideration in interpreting SURPASS-2 is the semaglutide dose used. The trial compared tirzepatide against semaglutide 1 mg (Ozempic), which is the diabetes dose. The higher 2.4 mg dose (Wegovy), approved for obesity, was not available as a comparator at the time of trial design.
This means the comparison was not against semaglutide's maximum potential. However, even accounting for this, the magnitude of tirzepatide's advantage — particularly at the 10 mg and 15 mg doses — suggests genuine superiority of the dual-agonist mechanism. This was later confirmed in the SURMOUNT-5 trial, which compared tirzepatide directly against semaglutide 2.4 mg for obesity [3].
Clinical Impact
SURPASS-2 had profound implications:
> Related Comparison: MOTS-C vs Metformin: Metabolic Comparison
> Related Comparison: Ozempic vs Mounjaro: Complete Comparison
References
---
> Want to explore this therapy under medical supervision? Telegenix offers telehealth consultations with providers who specialize in peptides and hormone optimization. Book your free consultation today.
---
Related Reading
Explore more in-depth guides on related topics:
For a comprehensive overview, see our Complete Guide to Peptide Therapy.
---